ImmuneOncia Therapeutics (424870)

KOSDAQ · 3,045 KRW · As of Aug 26, 2026 close

1Y Close · As of Aug 26, 2026

Mkt Cap

278.1B

Rev (2025)

111M

Op Inc (2025)

-28.0B

Net Inc (2025)

-27.4B

PBR

9.79

52W

2K~15K

ImmuneOncia Therapeutics operates in the Professional Services sector.

Legal name: ImmuneOncia Therapeutics, Inc.

In fiscal year 2025, ImmuneOncia Therapeutics (424870) reported revenue of 111 million KRW, down 83.0% from 655 million KRW a year earlier.

Operating profit was -28.0 billion KRW and net income was -27.4 billion KRW in the same year.

As of the Aug 26, 2026 close, the market capitalization was 278.1 billion KRW, with a P/B of 9.79.

These figures can be verified in the DART filing (receipt no. 20260318000757).

Year	Rev	Op Inc	Net Inc
2025	111M	-28.0B	-27.4B
2024	655M	-12.6B	-5.7B

2 applicable out of 8 items

Semi-Annual Report (2026.06)

Checks

2 of 8 checked items currently applicable.

Market Cap & Price: Market cap is above the delisting threshold.

Administrative Designation: 1 administrative designation criteria met. [source]

Audit Opinion: Audit opinion: Unqualified (clean).

Convertible Bonds: No convertible bonds outstanding.

Capital Increase: 1 capital-increase filing(s) in the last 180 days. [source]

Treasury Stock: No treasury stock filings.

Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.

Major Shareholder Change: No major shareholder changes in the last 180 days.

Market Action: No market actions recorded in the last 180 days.

These checks are mechanical tests of disclosed figures and do not constitute investment advice or recommendations.

Date	Filing
2026-08-14	Semi-Annual Report (2026.06)